Change of Adviser

Avacta Group plc ("Avacta" or "the Company") Change of Adviser Avacta Group plc (Stock Code: AVCT.L), an AIM listed company which provides novel detection and analysis technology for the pharmaceutical, defence/ security and clinical diagnostics markets, announces that it has appointed Daniel Stewart & Company plc as the Company's Nominated Adviser and Joint Broker with immediate effect. Novum Securities Limited continues to act as Joint Broker. 13 October 2008 Enquiries: Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer www.avacta.com Daniel Stewart & Company plc Tel: 020 7776 6550 Lindsay Mair/Tessa Smith www.danielstewart.co.uk Novum Securities Limited Tel: 020 7562 4700 Henry Turcan/Michael Brennan Haggie Financial LLP Tel: 020 7417 8989 Nicholas Nelson/Kathy Boate Nicholas.nelson@haggie.co.uk Notes to Editors: About Avacta Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by these core bio-analytical technologies. A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd, which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.
UK 100

Latest directors dealings